chang fair valu estim
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim oct
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
thank shift manag abl focu
structur competit advantag improv balanc sheet
judici step differ market even
vagari product cycl control roughli
 digit mammographi market lead way first
mammographi adopt slow still
opportun growth smaller hospit oversea
importantli clinic data still give edg
pricey gen-prob acquisit also hold top
posit host diagnost test focus women health
run sole proprietari instrument think
done good job capit prolifer low-
midvolum lab panther equip gain
traction expand recur revenu base
howev face secular competit hurdl
recommend cervic screen interv lengthen
reduc pap smear volum forc preserv
market share hpv price also fallen
dramat seek maintain share addit
heavy-weight siemen compet
mammographi market could challeng given ge
entrench select hospit abil bundl extens
menu capit equip
materi think done good job navig
pressur center medicar medicaid servic
establish reimburs mammographi appear
lucr firm custom base bolster
adopt believ first-mov advantag
mammographi wide instal base strong trial valid
provid firm foot market recent addit
cynosur provid entre aesthet market less
reliant reimburs broaden portfolio
translat even growth along line
larger med-tech firm enjoy
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
manufactur proprietari product healthcar need
women compani oper five segment breast health
sale diagnost surgic medic aesthet
skelet health compani tradit focus breast
health acquisit gen-prob put greater emphasi commerci
diagnost purchas cynosur establish footprint
cosmet laser market unit state account largest portion
firm revenu follow europ asia
bedford
headquart
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
chang fair valu estim
finish fiscal year strength
leav fair valu estim unchang see littl
materi alter estim fiscal sinc
project top bottom line well within
rang manag outlook though weve long thought
dug narrow econom moat basi
intang asset switch cost latest strateg
move serv reinforc firm moat
perspect particular like shift
breast health busi incorpor consum
product softwar upgrad go beyond sale
capit equip thank seri tuck-in acquisit
shape comprehens portfolio
mammographi biopsi expect stream on-going
innov breast health support mid-single-digit
growth seen recent unit
look forward develop introduct
artifici intellig product breast imag though
manag downplay growth expect
near term product optimist
potenti hold longer term rang clinic
studi consist suggest appli
element machin learn could significantli improv
rate accuraci mammogram especi reduc
number fals posit think strong
posit roll product given firm alreadi
leader mammographi enjoy larg instal
base also like product would tap
enhanc valu data captur mammogram
final reassur manag comment
success tuck-in acquisit strategi think
approach like help avoid larg expens
acquisit led major write-off past
includ gen-prob cynosur
hold steadi fair valu estim per
share holog abil rebuild legaci cynosur
commerci oper maintain gradual growth
digit mammographi upgrad cycl
launch new diagnost test key factor
valuat continu think firm well posit
roll-out panther instrument widen
stream recur test revenu also believ
holog entri viral-load test boost appeal
assay menu aid stabil hpv
test market intern side anticip
near-term expans europ slow entri
emerg market play greater role holog
top-lin growth forecast modest top-lin gain
surgic skelet health taken togeth along
addit cynosur project compound-annual-growth-rate
believ price pressur persist across
product forecast gross margin increas
increment firm increas recur
revenu higher-margin test servic expans
instal base mammographi equip
new salesforc medic aesthet becom
product midterm
believ firm sale mix capit equip
consum servic revenu translat averag
cash flow volatil warrant medium uncertainti
firm abil maintain instal base
diagnost instrument expand test
menu well quickli medic aesthet
segment return market-r growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
believ dug narrow econom moat base
switch cost intellectu properti
surround breast health diagnost platform
pioneer first fda-approv mammographi
platform continu expand instal
base unit mammographi equip
typic big-ticket purchas hospit
radiolog clinic price tag per digit
unit per instal time
retrain system reorgan work flow mean
custom littl incent switch platform
furthermor consider less expens
holog custom upgrad equip rather
switch compet system sizabl instal
base firm also reap benefit five-year servic
contract annual cost purchas
price option instal base
fall contract
addit lengthi fda approv process
sophist technolog tall barrier deter
new market entrant though gener electr
siemen receiv fda approv system
add new level competit could appli
price pressur think grow bodi clinic data
geniu system help establish superior
mind clinician two year
new competit yet seen soft
averag sell price
acquir gen-prob diagnost
divis also leverag high switch cost
surround proprietari instrument test
run ad thinprep lead share
liquid-bas pap market acquisit dramat
hpv
chlamydia gonorrhea trichomona blood screen
lab commit firm autom equip
streamlin oper run compani test
bull-cas scenario fair valu rise per
share assum introduct new assay lead
diagnost growth quicker-than-expect adopt
importantli project medic aesthet match
market growth annual fiscal though
slightli off-set less margin improv thank
greater proport medic aesthet
come lower margin
bearish scenario peg fair valu per
share assum greater competit price
pressur across busi segment hinder growth
particularli diagnost assum slowdown europ
emerg market significantli below-market
growth medic aesthet pressur rival
allergan also bake stringent requir
approv regulatori agenc translat
compound annual growth consolid
oper margin reach fiscal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
siemen receiv regulatori approv rival
enjoy strong brand name access greater resourc
technolog innov nevertheless uptak
platform remain solid size
compani digit instal base give us confid
maintain momentum upgrad despit new
entrant market remain competit
need maintain technolog edg equip
upgrad new product introduct appeal
within diagnost consider headwind pap
smear market seem eas diagnost oem
adjust longer recommend test interv
push annual pap smear closer everi three five
year women need continu
expand menu test appeal commerci
lab enhanc front-end autom capabl
instrument
overal feel firm well posit
front firm enter viral-load test hiv hep
 area billion market allianc quest could
also open menu expans opportun firm
co-develop promot new diagnost solut
consolid workflow fewer platform addit
time requir train lab technician adjust work flow
steep switch cost built around instrument
price tag built per-reag cost
addit cynosur provid sizabl
footprint aesthet market howev skeptic
busi bolster moat
cosmet laser market vulner disrupt technolog
low barrier entri rel low switch cost
littl clinic data differenti competit product
manufactur compet primarili basi market
offer possibl could build
meaning brand direct-to-consum commun
would contribut moat yet see
firm demonstr kind market chop would
take get
unfortun investor need exercis patienc
work rebuild commerci organ
support medic aesthet busi sinc
acquisit announc steadi stream cynosur
sale rep left must virtual rebuild entir
salesforc ground
think holog remain segment surgic
skelet health moat firm hysteroscop
surgic product myosur led pocket success
strong cash flow howev lower-cost altern
put pressur novasur product advers
macroeconom condit result mix skelet
result nevertheless believ breast health
diagnost segment
believ moat trend stabl within breast
health competit ramp ge
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
first market fda-approv
mammographi platform unit state give
consider head start gener electr
siemen
control lion share liquid-
base pap market gen-prob acquisit
catapult firm number-on posit
test chlamydia gonorrhea blood screen
ogovern reimburs mammographi
appear lucr custom base
acceler system placement
owith mammographi screen guidelin flux
potenti drop-off mammogram volum could hurt
product portfolio vari wide see
littl opportun effici use salesforc
call differ specialist
odespit full pipelin best effort high
degre clinic regulatori risk surround
product regulatori path approv
expens time-consum fruitless process
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
took consider leverag billion
acquisit gen-prob deleverag
ensu year avoid pile debt
purchas cynosur septemb owe
billion long-term debt held million cash
macmillan lead firm note prefer
oper firm substanti less leverag
balanc sheet held begin tenur
net debt/ebitda macmillan
balanc sheet typic held cash debt
set exceed goal time net debt/ebitda
end fiscal
believ sale mix capit equip
consum servic revenu translat averag
cash flow volatil warrant medium uncertainti
rate sale influenc capit spend
pattern hospit clinic could advers
affect prolong econom downturn effect
macroeconom downturn could exacerb
consum forgo cosmet laser treatment
interest tighten financi belt diagnost
market particip
also
competit firm sale could suffer screen
guidelin lengthen becom lenient furthermor
signific exposur regulatori risk
particularli within secur reimburs fda
approv new product introduct also
approxim sale come intern
market currenc headwind could neg impact
top- bottom-lin perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
board director
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
award holog standard mark stewardship
stephen macmillan step ceo late
macmillan formerli serv ceo
corpor hold
year oper experi healthcar
industri overal think macmillan well suit
job follow effect tenur execut
number success direct make sound
acquisit experi benefit
oper strategi macmillan also track record
gener free cash flow manag debt holog
benefit firm deleverag balanc
sheet follow gen-prob acquisit put holog
favor posit make acquisit broaden
firm footprint
primari complaint holog high-profil
acquisit come hefti price follow
substanti goodwil write-off rack
signific record substanti write-off last nine
year recent impair million
cynosur goodwil revalu goodwil led
billion impair charg relat third
wave gen-prob even earlier
billion relat cytyc acquisit entir
string impair reflect current
manag team recogn cumul
impact independ decis differ
manag team cost sharehold point
rather see buy back share embark
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
holog show sign strength fiscal third quarter
chang fair valu estim aug
sustain firm recent growth slight
adjust assumpt werent enough move
needl valuat remain confid
holog narrow econom moat pleas see
broad-bas strength across product line
quarter begin see firm reap
reward effort introduc increment innov
adjac technolog breast health increas
demand molecular diagnost especi assay
consid mid-tier size compar
larger competitor vitro diagnost breast
roch -- make sens expand
presenc addit complimentari product
market alreadi establish footprint
like eas fold breast imag biopsi
product exist portfolio leverag
instal base holog geniu
mammographi machin expect
acquisit super sonic imagin pair nice ad
ultrasound imag capabl compliment holog
presenc mammographi ultrasound imag often
follow step abnorm screen mammogram
use guid needl biopsi procedur
final see light end tunnel medic
aesthet busi though quarterli revenu
constant currenc definit improv
compar last four quarter declin seem
bottom fiscal second quarter expect
unit return growth new salesforc becom
product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end septemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
